NCT04429516View on ClinicalTrials.gov

Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Morphine Sulfate

over-encapsulated Morphine Sulfate prolonged release 5mg tablet, twice daily for 14 days. Patients will then crossover after a 7 day wash out period.

DRUG

Placebo oral tablet

capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily

Trial Locations (1)

SW3 6NP

Royal Brompton Hospital, London

All Listed Sponsors
lead

Royal Brompton & Harefield NHS Foundation Trust

OTHER

NCT04429516 - Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough | Biotech Hunter | Biotech Hunter